文献速递系统性红斑狼疮

缓解和低疾病活动度对系统性红斑狼疮患者健康相关生活质量的影响

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究利用BLISS-52和BLISS-76试验中1684例系统性红斑狼疮患者的数据,分析达到缓解或狼疮低疾病活动状态(LLDAS)的持续时间与健康相关生活质量(HRQoL)获益≥最小临床重要差异(MCID)之间的关系。结果显示,缓解和LLDAS均以时间依赖方式贡献HRQoL获益,且达到临床重要获益所需的缓解时间短于LLDAS时间;与躯体方面相比,精神方面HRQoL获益需要更长的缓解时间。当缓解/LLDAS持续维持时,可在更短时间内达到相同获益。

要点

  • 缓解和LLDAS以时间依赖方式贡献HRQoL获益。
  • 达到HRQoL临床重要获益所需的缓解时间短于LLDAS。
  • 精神HRQoL获益所需缓解时间长于躯体方面。

核心结论

  • 缓解和LLDAS以时间依赖方式贡献HRQoL获益。
  • 达到HRQoL临床重要获益所需的缓解时间短于LLDAS时间。
  • 精神方面HRQoL获益所需的缓解时间长于躯体方面。
  • 当缓解/LLDAS持续维持时,可在更短时间内达到相同获益。

研究设计与样本

  • 使用BLISS-52(NCT00424476)和BLISS-76(NCT00410384)试验中的简表36(SF-36)、三水平EQ-5D(EQ-5D-3L)和慢性病治疗功能评估-疲乏(FACIT-Fatigue)数据。
  • 采用分位数回归和广义估计方程确定治疗期间及治疗后达到HRQoL获益≥最小临床重要差异(MCID)所需的缓解/LLDAS持续时间。
  • 共纳入1684例患者,每四周评估一次,共15次访视。

主要发现

  • SF-36躯体成分总结(PCS)评分获益≥MCID需要4次累计(β=0.60)或4次连续(β=0.66)访视处于缓解。
  • SF-36精神成分总结(MCS)评分获益≥MCID需要6次累计(β=0.44)或5次连续(β=0.49)访视处于缓解。
  • LLDAS下PCS/MCS获益≥MCID均需要8次累计(β均为0.30)或8次连续(β均为0.32)访视。
  • EQ-5D-3L指数评分≥MCID需要6次累计(β=0.007)或5次连续(β=0.008)访视处于缓解,LLDAS下需要8次累计(β=0.005)或6次连续(β=0.006)访视。
  • FACIT-Fatigue评分≥MCID需要12次累计(β=0.34)或10次连续(β=0.39)访视处于缓解,LLDAS下需要17次累计(β=0.24)或16次连续(β=0.25)访视。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the impact of remission and lupus low disease activity state (LLDAS) on health-related quality of life (HRQoL) in systemic lupus erythematosus. METHODS: Short-Form 36 (SF-36), three-level EQ-5D (EQ-5D-3L) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials were used. Duration in remission/LLDAS required to reach a HRQoL benefit ≥ minimal clinically important differences (MCIDs) during and post-treatment was determined using quantile regression and generalized estimating equations. RESULTS: Patients (n = 1684) were assessed every fourth week (15 visits). Four cumulative (β = 0.60) or four consecutive (β = 0.66) visits in remission were required to achieve a benefit ≥MCID in SF-36 physical component summary (PCS) scores, and six cumulative (β = 0.44) or five consecutive (β = 0.49) for a benefit ≥MCID in mental component summary (MCS) scores. Eight cumulative (β = 0.30 for both) or eight consecutive (β = 0.32 for both) visits in LLDAS were required for a benefit in PCS/MCS ≥MCID, respectively. For EQ-5D-3L index scores ≥MCID, six cumulative (β = 0.007) or five consecutive (β = 0.008) visits in remission were required, and eight cumulative (β = 0.005) or six consecutive (β = 0.006) visits in LLDAS. For FACIT-Fatigue scores ≥MCID, 12 cumulative (β = 0.34) or 10 consecutive (β = 0.39) visits in remission were required, and 17 cumulative (β = 0.24) or 16 consecutive (β = 0.25) visits in LLDAS. CONCLUSION: Remission and LLDAS contribute to a HRQoL benefit in a time-dependent manner. Shorter time in remission than in LLDAS was required for a clinically important benefit in HRQoL, and longer time in remission for a benefit in mental compared with physical HRQoL aspects. When remission/LLDAS was sustained, the same benefit was achieved in a shorter time.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Emamikia S, Oon S, Gomez A, et al. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022. PMID: 35302581. doi:10.1093/rheumatology/keac185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。